Cargando…

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab

A significant association between high blood-based tumor mutational burden (bTMB) and improved progression-free survival (PFS) was observed in advanced non-small cell lung cancer (NSCLC) receiving atezolizumab. However, this result was unrepeatable in a recent prospective study. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Wei, Qian, Jie, Xu, Mi-Die, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Lu, Jun, Gan, Lu, Zhang, Xue-Yan, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Hu, Fang, Li, Chang-Hui, Zhong, Hua, Han, Bao-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051187/ https://www.ncbi.nlm.nih.gov/pubmed/32158623 http://dx.doi.org/10.1080/2162402X.2020.1731072

Ejemplares similares

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
por: Shang, Xiaoling, et al.
Publicado: (2021)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
por: Lu, Jun, et al.
Publicado: (2021)

Exploring the relationship between autophagy and Gefitinib resistance in NSCLC by silencing PDLIM5 using ultrasound-targeted microbubble destruction technology
por: Zhang, Yao, et al.
Publicado: (2022)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Ultrasound-sensitive siRNA-loaded nanobubbles fabrication and antagonism in drug resistance for NSCLC
por: Su, Chunhong, et al.
Publicado: (2021)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
por: Xia, Guohao, et al.
Publicado: (2023)

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
por: Peters, Solange, et al.
Publicado: (2022)

A Geometry-Based Cycle Slip Detection and Repair Method with Time-Differenced Carrier Phase (TDCP) for a Single Frequency Global Position System (GPS) + BeiDou Navigation Satellite System (BDS) Receiver
por: Qian, Chuang, et al.
Publicado: (2016)

HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells
por: Gu, Zhuoyu, et al.
Publicado: (2022)

Global, regional, and national burden of kidney dysfunction from 1990 to 2019: a systematic analysis from the global burden of disease study 2019
por: Zhang, Shu, et al.
Publicado: (2023)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods
por: Zhou, Jian-Guo, et al.
Publicado: (2022)

Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
por: Liu, Zhuochao, et al.
Publicado: (2021)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy
por: Yin, Wen-Jing, et al.
Publicado: (2021)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
por: Hu, Rong, et al.
Publicado: (2020)

CIAPIN1 Targeted NHE1 and ERK1/2 to Suppress NSCLC Cells' Metastasis and Predicted Good Prognosis in NSCLC Patients Receiving Pulmonectomy
por: Wang, Jian, et al.
Publicado: (2019)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
por: Takeuchi, Yasuto, et al.
Publicado: (2023)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis
por: Zhang, Meiling, et al.
Publicado: (2021)

Effect of prior therapy on tumor mutational burden in NSCLC
por: Jonna, Sushma, et al.
Publicado: (2021)

m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer
por: Chen, Mei, et al.
Publicado: (2019)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
por: Wang, Jing-Houng, et al.
Publicado: (2022)

Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device
por: Li, Xian-Ying, et al.
Publicado: (2017)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
por: Tan, Li-Ming, et al.
Publicado: (2019)

Impact of marital status on survival in patients with stage 1A NSCLC
por: Huang, Liu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h34ddo73e8sfjtqs15o1oov46u